Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 11Thoracic 10Tumor-Agnostic 9Lymphoid 5Dermatologic 5Breast 5Genitourinary 3CNS 3Gastrointestinal 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1Endocrine 1

Conditions

Recurrence 1Neoplasms 1Glioblastoma 1Gastrointestinal Stromal Tumors 1

Interventions

Temozolomide 62Cyclophosphamide 59Radiotherapy 47Doxorubicin 36Filgrastim 26Irinotecan 24Radiation 23Gemcitabine 23fludarabine 22Magnetic Resonance Spectroscopy 20Imatinib Mesylate 19Etoposide 18pembrolizumab 16Cisplatin 15Carboplatin 15Biopsy 15Bevacizumab 15Specimen Handling 14fludarabine phosphate 12Nivolumab 12Leucovorin 12Ipilimumab 12Granulocyte Colony-Stimulating Factor 12Chemotherapy, Adjuvant 12pazopanib 11Vincristine 11Ifosfamide 11Melphalan 10Erlotinib Hydrochloride 10Docetaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Midazolam × Sarcoma × Clear all
NCT04908176 2024-12-13

A Drug-drug Interaction Study of Avapritinib and Midazolam

Blueprint Medicines Corporation

Phase 1 Completed
10 enrolled
CNSGastrointestinalSarcoma

Glioblastoma, Neoplasms, Recurrence, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡